Skip to main contentSkip to navigationSkip to search
Curasight

The Share

Volume, thousands
[{"d":"2021-09-01","n":"Curasight A/S strengthens its institutional investor base","u":"/news/press-releases/2021/curasight-as-strengthens-its-institutional-investor-base/"},{"d":"2021-09-16","n":"The exercise period for warrants of series TO 1 in Curasight A/S begins today","u":"/news/press-releases/2021/the-exercise-period-for-warrants-of-series-to-1-in-curasight-as-begins-today/"},{"d":"2021-09-21","n":"Transactions with warrants of series TO 1 in Curasight A/S made by managerial employees and their closely associated persons","u":"/news/press-releases/2021/transactions-with-warrants-of-series-to-1-in-curasight-as-made-by-managerial-employees-and-their-closely-associated-persons/"},{"d":"2021-09-30","n":"Curasight warrant TO 1 – last day of trading is Tuesday 5 October 2021","u":"/news/press-releases/2021/curasight-warrant-to-1--last-day-of-trading-is-tuesday-5-october-2021/"},{"d":"2021-10-11","n":"Curasight A/S receives approximately DKK 47.6 million through exercise of warrants of series TO 1","u":"/news/press-releases/2021/curasight-as-receives-approximately-dkk-476-million-through-exercise-of-warrants-of-series-to-1/"},{"d":"2021-10-13","n":"Curasight A/S warrant exercise registered at Erhvervsstyrelsen","u":"/news/press-releases/2021/curasight-as-warrant-exercise-registered-at-erhvervsstyrelsen/"},{"d":"2021-10-15","n":"Curasight A/S presents at BioStock Life Science Summit 20 October 2021","u":"/news/press-releases/2021/curasight-as-presents-at-biostock-life-science-summit-20-october-2021/"},{"d":"2021-10-15","n":"Curasight A/S presents at Økonomisk Ugebrev Life Science Investor Conference in Copenhagen 20 October 2021","u":"/news/press-releases/2021/curasight-as-presents-at-okonomisk-ugebrev-life-science-investor-conference-in-copenhagen-20-october-2021/"},{"d":"2021-11-23","n":"Curasight presents at HC Andersen Capital","u":"/news/press-releases/2021/curasight-presents-at-hc-andersen-capital-2021-11-23/"},{"d":"2021-11-25","n":"Interim report January – September 2021","u":"/news/press-releases/2021/interim-report-january--september-2021/"},{"d":"2021-12-06","n":"Curasight A/S presents at Sedermeradagen in Copenhagen 7 December 2021","u":"/news/press-releases/2021/curasight-as-presents-at-sedermeradagen-in-copenhagen-7-december-2021/"},{"d":"2021-12-07","n":"Curasight A/S presents at HC Andersen Capital & Nordea Markets Virtual Growth Days seminar - 9 December 2021","u":"/news/press-releases/2021/curasight-as-presents-at-hc-andersen-capital--nordea-markets-virtual-growth-days-seminar---9-december-2021/"},{"d":"2021-08-24","n":"Interim report January – June 2021","u":"/news/press-releases/2021/interim-report-january--june-2021/"},{"d":"2021-08-23","n":"Curasight presents at HC Andersen Capital","u":"/news/press-releases/2021/curasight-presents-at-hc-andersen-capital/"},{"d":"2021-02-08","n":"US patent application 14/399,820 relating to uTREAT[®] is accepted for grant","u":"/news/press-releases/2021/us-patent-application-14399820-relating-to-utreat-is-accepted-for-grant/"},{"d":"2021-02-24","n":"Year-end report October – December 2020","u":"/news/press-releases/2021/year-end-report-october--december-2020/"},{"d":"2021-02-24","n":"Annual Report for the fiscal year 2020","u":"/news/press-releases/2021/annual-report-for-the-fiscal-year-2020/"},{"d":"2021-02-26","n":"Article from Phase II study in prostate cancer now published in the March issue of Journal of Nuclear Medicine and highlighted as best clinical investigation article","u":"/news/press-releases/2021/article-from-phase-ii-study-in-prostate-cancer-now-published-in-the-march-issue-of-journal-of-nuclear-medicine-and-highlighted-as-best-clinical-investigation-article/"},{"d":"2021-03-05","n":"Curasight A/S presents at Økonomisk Ugebrev Life Science Investor Conference","u":"/news/press-releases/2021/curasight-as-presents-at-okonomisk-ugebrev-life-science-investor-conference/"},{"d":"2021-03-11","n":"Notice of Annual General Meeting","u":"/news/press-releases/2021/notice-of-annual-general-meeting/"},{"d":"2021-03-11","n":"Curasight’s presentation at Økonomisk Ugebrev Life Science Investor Conference is now available","u":"/news/press-releases/2021/curasights-presentation-at-okonomisk-ugebrev-life-science-investor-conference-is-now-available/"},{"d":"2021-03-25","n":"Minutes from the Annual General Meeting in Curasight A/S","u":"/news/press-releases/2021/minutes-from-the-annual-general-meeting-in-curasight-as/"},{"d":"2021-03-28","n":"CAD patent application 2,905,172 relating to uTREAT[®] is accepted for grant","u":"/news/press-releases/2021/cad-patent-application-2905172-relating-to-utreat-is-accepted-for-grant/"},{"d":"2021-04-09","n":"Curasight A/S presents at Nordnet Live - Spotlight Small Cap investor conference 15 April 2021","u":"/news/press-releases/2021/curasight-as-presents-at-nordnet-live---spotlight-small-cap-investor-conference-15-april-2021/"},{"d":"2021-05-04","n":"Curasight announces appointment of Dr. Kirsten Drejer as new board member","u":"/news/press-releases/2021/curasight-announces-appointment-of-dr-kirsten-drejer-as-new-board-member/"},{"d":"2021-05-17","n":"Curasight is awarded two prizes in Best IPO 2020 by the independent IPO Guide","u":"/news/press-releases/2021/curasight-is-awarded-two-prizes-in-best-ipo-2020-by-the-independent-ipo-guide/"},{"d":"2021-05-18","n":"Notice of Extraordinary General Meeting","u":"/news/press-releases/2021/notice-of-extraordinary-general-meeting/"},{"d":"2021-05-20","n":"Interim report January – March 2021","u":"/news/press-releases/2021/interim-report-january--march-2021/"},{"d":"2021-05-20","n":"Interim report January – March 2021 – Correction","u":"/news/press-releases/2021/interim-report-january--march-2021--correction/"},{"d":"2021-05-21","n":"Curasight presents at Erik Penser Bank – Temadag Medicinsk Bildteknik & Diagnostik","u":"/news/press-releases/2021/curasight-presents-at-erik-penser-bank--temadag-medicinsk-bildteknik--diagnostik/"},{"d":"2021-05-26","n":"Curasight presents at Bio Stock Life Science Spring Summit","u":"/news/press-releases/2021/curasight-presents-at-bio-stock-life-science-spring-summit/"},{"d":"2021-06-01","n":"Minutes from the Extraordinary General Meeting in Curasight A/S","u":"/news/press-releases/2021/minutes-from-the-extraordinary-general-meeting-in-curasight-as/"},{"d":"2021-06-18","n":"SEB initiates commissioned research on Curasight A/S","u":"/news/press-releases/2021/seb-initiates-commissioned-research-on-curasight-as/"},{"d":"2021-06-24","n":"Positive data of uTREAT® in glioblastoma provides “green light” to proceed with next steps","u":"/news/press-releases/2021/positive-data-of-utreat-in-glioblastoma-provides-green-light-to-proceed-with-next-steps/"},{"d":"2020-09-03","n":"The subscription period in Curasight’s issue of units starts today","u":"/news/press-releases/2020/the-subscription-period-in-curasights-issue-of-units-starts-today/"},{"d":"2020-09-02","n":"Curasight A/S receives approval for listing and publishes prospectus","u":"/news/press-releases/2020/curasight-as-receives-approval-for-listing-and-publishes-prospectus/"},{"d":"2020-09-09","n":"Webcast with Curasight","u":"/news/press-releases/2020/webcast-with-curasight/"},{"d":"2020-09-22","n":"Significantly oversubscribed IPO of units in Curasight","u":"/news/press-releases/2020/significantly-oversubscribed-ipo-of-units-in-curasight/"},{"d":"2020-10-08","n":"First day of trading in Curasight’s shares and warrants at Spotlight Stock Market","u":"/news/press-releases/2020/first-day-of-trading-in-curasights-shares-and-warrants-at-spotlight-stock-market/"},{"d":"2020-10-07","n":"Prolongation and expansion of agreement with TRT Innovations ApS","u":"/news/press-releases/2020/prolongation-and-expansion-of-agreement-with-trt-innovations-aps/"},{"d":"2020-10-22","n":"Canadian patent application relating to uTRACE[®] is ready for allowance in Canada","u":"/news/press-releases/2020/canadian-patent-application-relating-to-utrace-is-ready-for-allowance-in-canada/"},{"d":"2020-11-11","n":"Curasight initiates pre-clinical study on therapy (uTREAT[®]) in brain cancer and signs CRO-agreement","u":"/news/press-releases/2020/curasight-initiates-pre-clinical-study-on-therapy-utreat-in-brain-cancer-and-signs-cro-agreement/"},{"d":"2020-11-30","n":"Interim report January – September 2020","u":"/news/press-releases/2020/interim-report-january--september-2020/"},{"d":"2020-12-15","n":"Financial Calendar 2021","u":"/news/press-releases/2020/financial-calendar-2021/"},{"d":"2020-12-16","n":"Japanese patent application 2019-005811 is accepted for grant","u":"/news/press-releases/2020/japanese-patent-application-2019-005811-is-accepted-for-grant/"},{"d":"2020-12-21","n":"Results from Phase II study in prostate cancer to be published in the Journal of Nuclear Medicine","u":"/news/press-releases/2020/results-from-phase-ii-study-in-prostate-cancer-to-be-published-in-the-journal-of-nuclear-medicine/"}]
Download as Excel

Trades

Price Volume Buyer Seller Time

Order book

Buy Volume     Volume Sell